Clinical Trials Directory

Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

The goal of the first part of this clinical trial (Phase I portion) is to study the side effects, drug breakdown (pharmacokinetics), and dosing of the drug MLN8237 (alisertib) when added to standard chemotherapy drugs, irinotecan and temozolomide. The goal of the second part of this clinical trial (Phase II portion) is to learn how many children and young adults show improvements in their neuroblastoma when treated with the combination of MLN8237, irinotecan, and temozolomide.

Stanford is now accepting new patients for this trial. Please contact Pediatric Hematology/Oncology at 650-723-5535 for more information.



  • drug : MLN8237
  • drug : Temozolomide
  • drug : Irinotecan

Phase: Phase 1/Phase 2


Ages Eligible For Study:

12 Months - 30 Years

External Links

Explore related trials

Contact information

Primary Contact:

Pediatric Hematology/Oncology 650-723-5535

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: